Peptides & Amino Acids

SB-peptide offers the scrambled version of MAGE-A p248V9. RQYVELPYV can be used as a negative control of MAGE-A p248V9 studies. SB-peptide offers also MAGE-A p248V9 (see section MAGE-A p248V9)). MAGE-A protein: MAGE-A p248V9, also kwon as multi-MAGE-A (YLEYRQVPV) is an epitope of Melanoma Antigen Gene expressed by tumors of different histological types and is a Cancer/Testis Antigens (CTA). Type of MAGE-A expressed in tumors cells varies according to the type of tumor. Targeting epitopes shared by all MAGE-A antigens would be interest in immunotherapy against a broad spectrum of cancers. Applications of MAGE-A p248V9 (multi-MAGE-A) : MAGE-A p248V9 is very useful because it could generate an HLA-A*02:01-restricted CTL response and shared by MAGE-A1,-A2,-A3,-A4,-A6,-A10 and -A12. MAGE-A p248V9 is used to stimulate specific cytotoxic T lymphocytes (CTL) in PBMCs and then to analyze CTL response especially the cytokine production by ELISPOT assay. Sequence : RQYVELPYV

SB-peptide offers the scrambled version of Melan-A/MART-1 (26-35). AIEIAGGLTV can be used as a negative control of Melan-A/MART-1 (26-35) studies. SB-peptide offers also Melan-A/MART-1 (26-35) (see section Melan-A/MART-1 (26-35)). Native Melan-A (26-35) decapepetide derives from the melanocyte lineage-specific protein Melan-A/MART-1, which is expressed in almost 75-100% of primary and metastatic melanomas1. The region 26-35 of Melan-A protein acts as an antigenic peptide that is recognized by CD8+ tumor-reactive cytolytic T lymphocytes (CTLs) for designing antigen-specific cancer vaccines1. It has been shown that CD8+ Melan-A-specific CTLs isolated from melanoma patients efficiently lyse the Melan-A-expressing HLA-A*0201+ melanoma cell line. However, CTLs preferentially recognize the Melan-A (26-35) peptide as compared with the Melan-A (27-35) peptide1. Moreover, the Melan-A (26-35) A27L analog (ELAGIGILTV) has a higher binding affinity to HLA-A*0201 than the native Melan-A (26-35) pe

SB-peptide offers the scrambled version of MAGE-A2 (157-166). VLVYFQEIGL can be used as a negative control of MAGE-A2 (157-166) studies. SB-peptide offers also MAGE-A2 (157-166) (see section MAGE-A2 (157-166)). MAGE-A2 protein: MAGE-A2 (157-166) is an epitope of Melanoma Antigen Gene A2 and is one of the most Cancer-Testis Antigens (CTA) overexpressed in tumors of different histological types, such as prostate cancer. Type of MAGE-A expressed in tumors cells varies according to the type of tumor. The expression of MAGE-A2 causes the proliferation of prostate cancer cells and decreases the chemosensitivity. Applications of MAGE-A2 (157-166): MAGE-A2 (157-166) is used to stimulate specific immune response, cytotoxic T cell response and to analyze the cytokine production in PBMCs by ELISPOT assay. In transgenic mouse, it has been demonstrated that MAGE-A2 (157-166) was capable of eliciting a CTL response presented by HLA-A*02:01 molecules. MAGE-A2 (157-166) has been reported to elicit C

SB-peptide offers the scrambled version of MAGE-A1 (278-286). ELIVKVYKV can be used as a negative control of MAGE-A1 (278-286) studies. SB-peptide offers also MAGE-A1 (278-286) (see section MAGE-A1 (278-286)). MAGE-A1 protein: MAGE-A1 (278-286) is an epitope of Melanoma Antigen Gene A1 expressed by tumors of different histological types such as on the surface of breast carcinoma cell and is a Cancer/Testis Antigens (CTA). MAGE-A1 is a tumor antigen expressed in 40% of melanoma and contains epitope for binding HLA-A*02:01 molecules and that are recognized by cytotoxic T cells. Applications of MAGE-A1 (278-286): MAGE-A1 (278-286) is used to stimulate specific cytotoxic T cells in PBMCs and to analyze by ELISPOT peptide epitope specificity and cytokine production like IFN-γ. Immunogenicity of MAGE-A1 (278-286) raised the possibility of developing anticancer immunotherapies or vaccinations. MAGE-A1 is also expressed in lung adenocarcinoma and studies suggest that MAGE-A1 may serve to dev

SB-peptide offers the scrambled version of PADRE peptide. AAATLWKAAKFVA can be used as a negative control of PADRE peptide studies. SB-peptide offers also PADRE peptide (see section PADRE peptide). PADRE peptide: Pan HLA DR-binding epitope is a universal peptide that activates antigen specific-CD4+ T cells which can be used as an agonist adjuvant in immunotherapeutic vaccine development. Pan HLA DR-binding epitope has been proposed as a carrier epitope suitable for use in the development of synthetic and recombinant vaccines. It has been demonstrated that PADRE may be an universal approach to control tumor cells. Moreover, PADRE is also used in research about an immunosense approach to develop a base for development of vaccines against toxoplasmosis to protect person with HLA-A*03 type. Pan HLA DR-binding epitope can be also used as tool to study the autoreactive T cell response.

SARS-CoV-2 Spike RBD 319-335 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 319-335 peptide is useful for vaccine development and for structure-activity relationship studies SARS-CoV-2 Spike (S) glycoprotein Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells. With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 319-335 (Biotin-LC) peptide

SARS-CoV-2 Spike RBD 336-347 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 336-347 peptide is useful for vaccine development and for structure-activity relationship studies SARS-CoV-2 Spike (S) glycoprotein Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells. With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 336-347 (Biotin-LC) peptide

SARS-CoV-2 Spike RBD 348-357 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 348-357 peptide is useful for vaccine development and for structure-activity relationship studies SARS-CoV-2 Spike (S) glycoprotein Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells. With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 348-357 (Biotin-LC) peptide

SARS-CoV-2 Spike RBD 352-365 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 352-365 peptide is useful for vaccine development and for structure-activity relationship studies SARS-CoV-2 Spike (S) glycoprotein Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells. With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 352-365 (Biotin-LC) peptide